Is a family history of hypertrophic cardiomyopathy an indication for a fetal echocardiogram?

Family History of Hypertrophic Cardiomyopathy and Fetal Echocardiography

Yes, a family history of hypertrophic cardiomyopathy is an indication for fetal echocardiography, particularly in families with early-onset disease, severe manifestations, or when a pathogenic mutation has been identified in a parent.

Primary Indication Based on Guidelines

The 2024 AHA/ACC guideline explicitly states that fetal echocardiography is available for prenatal diagnosis of HCM and is used in select families, particularly if there is a history of pediatric disease onset or severe disease manifestations in parents or other family members 1. This represents the most current and authoritative guidance on this specific question.

Risk Assessment Framework

The decision to pursue fetal echocardiography should be based on:

High-Risk Scenarios (Strong Indication)

• Known pathogenic mutation in parent: HCM follows autosomal dominant inheritance with 50% transmission risk to each offspring 2
• Early-onset disease in family: Pediatric presentation suggests more aggressive phenotype
• Malignant family history: Premature death from HCM or severe complications 2
• Severe parental phenotype: Massive hypertrophy, heart failure, or multiple adverse events

Lower-Risk Scenarios (Selective Use)

• Late-onset HCM diagnosed in elderly relative with mild phenotype 3
• Single affected family member with benign course
• Genotype-elusive families (no mutation identified) 3

Timing and Technical Considerations

Optimal timing for fetal echocardiography is 18-22 weeks gestation 4, though evaluation can be performed throughout pregnancy if clinical suspicion arises. The examination should include:

• Ventricular wall thickness measurements
• Assessment for asymmetric septal hypertrophy
• Evaluation for left ventricular outflow tract obstruction
• Doppler assessment of cardiac function

Important Caveats

1. Normal fetal echo does not exclude future disease: The probability of cardiac expression in the fetus is extremely low 5. Most individuals with HCM mutations develop phenotypic expression during adolescence or early adulthood, not in utero 2, 6.

2. Postnatal surveillance remains essential: Even with normal prenatal imaging, children at risk require serial echocardiographic screening starting no later than puberty, with frequency based on age and genetic status 2, 7.

3. Distinguish from maternal diabetes: Transient fetal hypertrophic cardiomyopathy is common in diabetic pregnancies (92.3% association in one series) 8 and typically regresses postnatally—this is distinct from familial HCM.

Clinical Algorithm

For pregnant women with HCM or family history:

1. Establish genetic status if possible before or during pregnancy
2. If pathogenic mutation identified in parent → Offer fetal echocardiography at 18-22 weeks
3. If family history of early-onset or severe HCM → Consider fetal echocardiography even without confirmed mutation
4. If mild, late-onset disease in single relative → Fetal echo optional; focus on postnatal screening plan
5. All at-risk infants → Postnatal echocardiography within first 3 months regardless of prenatal findings 9

Genetic Counseling Integration

Prenatal genetic counseling should precede fetal echocardiography 1 to discuss:

• 50% transmission risk with autosomal dominant inheritance
• Reproductive options including preimplantation genetic testing
• Limitations of prenatal diagnosis (low fetal expression rate)
• Need for lifelong postnatal surveillance regardless of fetal findings

The yield of fetal echocardiography for detecting HCM is relatively low given the rarity of in utero phenotypic expression 5, but it provides valuable information in high-risk families and can guide delivery planning and immediate neonatal management when abnormalities are detected 10, 9, 11.